CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD.

Chengdu Easton Biopharmaceuticals Co., Ltd.

688513

CNE100004397

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
58.02 ^CNY	-0.99%		-5.32%	-9.03%

04-22	Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	Easton Biopharma's Unit Gets Nod to Market Bisoprolol Amlodipine Tablets	MT

Chengdu Easton Biopharmaceuticals Co., Ltd.(XSSC:688513) added to S&P Global BMI Index

September 18, 2023 at 12:00 am

Latest news about Chengdu Easton Biopharmaceuticals Co., Ltd.

Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-22	CI
Easton Biopharma's Unit Gets Nod to Market Bisoprolol Amlodipine Tablets	04-16	MT
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Tranche Update on Chengdu Easton Biopharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on August 14, 2023.	01-03	CI
Chengdu Easton Registers Heart Failure Drug	12-19	MT
Chengdu Easton Biopharmaceuticals Co., Ltd.(XSSC:688513) dropped from S&P Global BMI Index	12-18	CI
Chengdu Easton Biopharma Registers Ibuprofen Injection For Premature Babies	11-21	MT
Chengdu Easton Biopharmaceuticals' Unit Gets US FDA's Nod for Nalmefene Hydrochloride Injection; Shares Rise 5%	11-17	MT
Chengdu Easton Biopharma Registers Hypertension Drug	11-01	MT
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Chengdu Easton Biopharma Registers Blood Pressure Control Drug	23-10-24	MT
Chengdu Easton Biopharma's Antiepileptic Drug Gets Marketing Nod in China	23-10-18	MT
Tranche Update on Chengdu Easton Biopharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on August 14, 2023.	23-10-10	CI
Easton Biopharma Unit's Production Line Passes US FDA Inspection	23-09-25	MT
Chengdu Easton Biopharmaceuticals Co., Ltd.(XSSC:688513) added to S&P Global BMI Index	23-09-18	CI
Certain A Shares of Chengdu Easton Biopharmaceuticals Co., Ltd. are subject to a Lock-Up Agreement Ending on 2-SEP-2023.	23-09-01	CI
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
Chengdu Easton Biopharma to Repurchase Up to 200 Million Yuan Shares	23-08-15	MT
Chengdu Easton Biopharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	23-08-14	CI
Chengdu Easton Biopharmaceuticals Co., Ltd. authorizes a Buyback Plan.	23-08-13	CI
Chengdu Easton Biopharmaceuticals Registers Schizophrenia Drug in China	23-08-04	MT
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-20	CI
Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-27	CI

Chart Chengdu Easton Biopharmaceuticals Co., Ltd.

Duration

Period

Chart Chengdu Easton Biopharmaceuticals Co., Ltd.

More charts

Chengdu Easton Biopharmaceuticals Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The Company's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The Company operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Chengdu Easton Biopharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

58.02

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD.	-9.03%	966M
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals